OZARK, MO, September 17, 2026 — Sharlin Health and Neurology announced that its approach to investigational stem cell and exosome therapies emphasizes structured neurological evaluation, product-quality review, patient risk screening, informed consent, and objective follow-up before regenerative options are considered within a broader care plan.

The clinical framework reflects growing patient interest in stem cell and exosome therapies for neurological conditions while scientific evidence and regulatory standards continue to develop. The practice states that regenerative potential should be evaluated separately from proven clinical benefit and that investigational therapies should not replace established neurological care.

Patient evaluation begins with confirmation of the neurological diagnosis, disease stage, current medications, previous testing, and available standard treatment options. Additional screening considers factors including active infection, cancer history, immune suppression, bleeding or clotting concerns, cardiovascular instability, uncontrolled diabetes, kidney or liver disease, pregnancy, recent surgery, and the patient’s ability to tolerate the proposed procedure.

Product review is incorporated into the assessment process. For stem cell products, relevant documentation may include tissue source, cell identity, viability, sterility testing, processing procedures, storage conditions, lot identification, and chain of custody. Exosome and extracellular vesicle products may require review of cell source, purification methods, particle characterization, concentration, sterility testing, potency testing, storage requirements, and lot-specific documentation.

The practice also evaluates administration methods as part of the risk assessment. Routes discussed in regenerative medicine include intravenous, intramuscular, local tissue, intranasal, and intrathecal administration, with each approach carrying different procedural considerations. Intrathecal administration requires particular attention to sterile technique, patient selection, and plans for identifying and managing complications involving the central nervous system.

Sharlin Health and Neurology incorporates regenerative options within its Brain Tune Up! clinical framework, which organizes care around diagnosis, investigation of contributing health factors, integration of conventional and supportive interventions, restoration of underlying metabolic and physiological factors, and consideration of regenerative approaches after foundational evaluation has been completed.

The practice also emphasizes baseline measurement and structured follow-up when investigational regenerative therapies are considered. Depending on the neurological condition, monitoring may include neurological examination findings, walking and balance testing, strength measurements, cognitive assessments, activities of daily living, imaging, laboratory markers, medication use, and other documented clinical measures.

Current clinical evidence described by the practice indicates that some mesenchymal stromal cell studies have reported acceptable short-term tolerability under controlled research protocols, while larger randomized trials and longer follow-up remain necessary. Evidence involving exosome therapy in neurological disease remains more limited, and commercially marketed products may differ substantially in manufacturing, characterization, dosing, and administration methods.

The practice will continue using structured neurological assessment, documented product-quality review, informed consent, and objective monitoring when evaluating investigational regenerative options as research, regulatory guidance, and clinical evidence continue to evolve.

Media Contact

Sharlin Health and Neurology
Phone: +1 417-485-4330
Email: callie@sharlinfxmed.com
Website: Sharlin Health and Neurology

About Sharlin Health and Neurology

Sharlin Health and Neurology provides neurological care incorporating conventional evaluation, functional medicine principles, advanced diagnostics, and structured care planning. The practice considers investigational regenerative approaches within broader neurological care frameworks that include diagnostic review, patient screening, risk assessment, and ongoing clinical monitoring.

Contact Information:

Sharlin Health & Neurology functional Medicine

5528 North Farmer Branch Road
Ozark, MO 65721
United States

Ken Sharlin
(417) 485-4330
https://functionalmedicine.doctor/